PureTech's deupirfenidone shows positive results in slowing lung function decline in IPF patients

From Nasdaq: 2024-12-16 02:31:18

PureTech Health plc announced positive results from the ELEVATE IPF trial, a Phase 2b study evaluating deupirfenidone in patients with idiopathic pulmonary fibrosis. The trial met its primary endpoint, showing a 98.5% probability that deupirfenidone was superior to placebo in slowing lung function decline. Results also demonstrated a dose-dependent response, with deupirfenidone 825 mg TID showing a treatment effect of 80.9%. Deupirfenidone 825 mg TID also had a statistically significant benefit on forced vital capacity percent predicted. PureTech plans to discuss these results with regulatory authorities for further development.



Read more at Nasdaq: PureTech’s Deupirfenidone Shows Positive Results In Slowing Lung Function Decline In IPF Patients